# Dermatologic Agents - Topical Acne Products

|||
| ---------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Criteria 1 | NP- Amzeeq, Azelaic Acid Gel, Benzoyl Peroxide Foam, Clindacin Kit, Clindamycin Foam, Clindamycin Swabs, Dapsone Gel, Epsolay, Finacea Foam, Onexton Gel, Ovace Plus, Sodium Sulfacetamide/Sulfur Gel, Sodium Sulfacetamide Pads, Winlevi |
| Criteria 2 | NP Agents- Topical Retinoids (all have AR)- Adapalene Cream, Adapalene Sol 0.1%, Adapalene Gel 0.3%, Adapalene/Benzoyl Peroxide, Aklief, Altreno, Arazlo, Clindamycin/Tretinoin, Plixda, Tazarotene Foam 0.1%, Tazarotene Gel 0.1%        |
| Criteria 3 | NP Criteria- Twyneo (NP, AR)                                                                                                                                                                                                              |
| Criteria 4 | NP Criteria - Tazarotene Cream (NP, AR)                                                                                                                                                                                                   |
| Criteria 5 | Topical Retinoids- Adapalene Gel 0.1% (P, AR), Tretinoin (P, AR)                                                                                                                                                                          |

## Non-Preferred Products: Non-Retinoids 

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Dermatologic Agents: Topical Acne Products</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products: Non-Retinoids</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>AMZEEQ</td>
<td>080360</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>AZELAIC ACID GEL</td>
<td>051812</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>BENZOYL PEROXIDE FOAM</td>
<td>065589</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>BENZOYL PEROXIDE FOAM</td>
<td>066879</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>BENZOYL PEROXIDE FOAM</td>
<td>080592</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>CLINDACIN KIT</td>
<td>067124</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>CLINDAMYCIN FOAM, SWABS</td>
<td>058418</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>CLINDAMYCIN FOAM, SWABS</td>
<td>022140</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>DAPSONE GEL</td>
<td>061136</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>DAPSONE GEL</td>
<td>075635</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>EPSOLAY</td>
<td>083337</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FINACEA FOAM</td>
<td>074590</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ONEXTON GEL</td>
<td>073195</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>OVACE PLUS</td>
<td>053380</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>OVACE PLUS</td>
<td>063084</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>OVACE PLUS</td>
<td>065889</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>OVACE PLUS</td>
<td>072502</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>OVACE PLUS</td>
<td>073027</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SODIUM SULFACETAMIDE/SULFUR GEL</td>
<td>073027</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>SODIUM SULFACETAMIDE PADS</td>
<td>057943</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>SODIUM SULFACETAMIDE PADS</td>
<td>064589</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>WINLEVI</td>
<td>081428</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">30 days</span> of at least <span class="underline">three preferred</span> drugs?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td> Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>8</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>9</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

|||
| ------------------ | --------- |
| **Last Approved ** | 4/24/2023 |
| **Other**          |           |

## Non-Preferred Products: Retinoids

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Dermatologic Agents: Topical Acne Products</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products: Retinoids</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>ADAPALENE CREAM, SOL 0.1%</td>
<td>031789</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADAPALENE CREAM, SOL 0.1%</td>
<td>066179</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ADAPALENE GEL 0.3%</td>
<td>062811</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADAPALENE GEL 0.3%</td>
<td>068878</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ADAPALENE/BENZOYL PEROXIDE</td>
<td>068880</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ADAPALENE/BENZOYL PEROXIDE</td>
<td>074495</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>AKLIEF</td>
<td>080265</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>ALTRENO</td>
<td>078800</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>ARAZLO</td>
<td>080595</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>CLINDAMYCIN/TRETINOIN</td>
<td>061775</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>PLIXDA</td>
<td>045146</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TAZAROTENE FOAM 0.1%</td>
<td>069204</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0997</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request) </td>
<td>0998</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0998</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>0999</td>
<td></td>
<td> Select  </td>
<td><p>Does the patient have a diagnosis of skin cancer? </p>
<p> </p></td>
<td> Y   </td>
<td> END (Approve x 365 days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td> N   </td>
<td>1000</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> of at least <span class="underline">three preferred</span> drugs?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>6</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1004</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1004</td>
<td></td>
<td> Select </td>
<td>Is the patient 24 years of age and older? </td>
<td>Y </td>
<td> 1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td> END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>10</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>11</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

|||
| ------------------ | ------------------------------------------------------------------------------ |
| **Last Approved ** | 4/24/2023                                                                      |
| **Other**          | If 24 or older, must meet criteria and have a diagnosis of acne or skin cancer |

## Twyneo

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Dermatologic Agents: Topical Acne Products</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Twyneo</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>TWYNEO</td>
<td>082535</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0997</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0998</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0998</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>0999</td>
<td></td>
<td> Select  </td>
<td><p>Does the patient have a diagnosis of skin cancer? </p>
<p> </p></td>
<td> Y   </td>
<td> END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td> N   </td>
<td>1000</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> of at least <span class="underline">three preferred</span> drugs?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>6</td>
<td>1002</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation for the patient’s inability to use the individual drugs?</p>
<p>If yes, please submit documentation.</p></td>
<td>Y   </td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1003</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1005</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1004</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1005</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1005</td>
<td></td>
<td> Select </td>
<td>Is the patient 24 years of age and older? </td>
<td>Y </td>
<td> 1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td> END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y    </td>
<td>END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>11</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>12</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

|||
| ------------------ | --------------------------------------------------------------- |
| **Last Approved ** | 4/24/2023                                                       |
| **Other**          | If 24 or older, must meet criteria and have a diagnosis of acne |

## Tazorac 0.1% Cream

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Dermatologic Agents: Topical Acne Products</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Tazorac 0.1% Cream</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>TAZAROTENE 0.1% CREAM</td>
<td>046984</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TAZAROTENE GEL 0.1%</td>
<td>031601</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0996</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0997</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0997</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>0998</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>0998</td>
<td></td>
<td> Select  </td>
<td><p>Does the patient have a diagnosis of skin cancer? </p>
<p> </p></td>
<td> Y   </td>
<td> END (Pending Manual Review) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td> N   </td>
<td>0999</td>
</tr>
<tr class="odd">
<td>4</td>
<td>0999</td>
<td></td>
<td>Select  </td>
<td><p>Does the patient have a diagnosis of psoriasis? </p>
<p> </p></td>
<td> Y   </td>
<td>END (Approve x 365 days) </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td> N   </td>
<td>1000</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">90 days</span> of at least <span class="underline">three preferred</span> drugs?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>7</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1004</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1004</td>
<td></td>
<td> Select </td>
<td>Is the patient 24 years of age and older? </td>
<td>Y </td>
<td> 1235 </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td> END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>10</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td>Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>11</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>12</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

|||
| ------------------ | --------------------------------------------------------------- |
| **Last Approved ** | 4/24/2023                                                       |
| **Other**          | If 24 or older, must meet criteria and have a diagnosis of acne |

## Preferred Products: Retinoids

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Dermatologic Agents: Topical Acne Products</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Preferred Products: Retinoids</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>ADAPALENE GEL 0.1%</td>
<td>026436</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRETINOIN</td>
<td>005797</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRETINOIN</td>
<td>005798</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRETINOIN</td>
<td>005799</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRETINOIN</td>
<td>005800</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRETINOIN</td>
<td>005801</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRETINOIN</td>
<td>021108</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRETINOIN</td>
<td>030614</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRETINOIN</td>
<td>050417</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRETINOIN</td>
<td>068881</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRETINOIN</td>
<td>068882</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRETINOIN</td>
<td>072395</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>TRETINOIN</td>
<td>077907</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>TRETINOIN</td>
<td>046783</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1</td>
<td>1234</td>
<td></td>
<td>Select</td>
<td><p>Is the patient 24 years and older?</p>
<p>Please note: a PA is only required for patients 24 years and older.</p></td>
<td>Y</td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1236</td>
</tr>
<tr class="odd">
<td>2</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>3</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>A PA is not required for those younger than 24 years of age.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

LENGTH OF AUTHORIZATIONS: 365 Days 

|||
| ------------------ | ------------------------------------------------------------------------------ |
| **Last Approved ** | 4/24/2023                                                                      |
| **Other**          | If 24 or older, must meet criteria and have a diagnosis of acne or skin cancer |
